239 related articles for article (PubMed ID: 24468632)
1. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.
Tardy S; Orsato A; Mologni L; Bisson WH; Donadoni C; Gambacorti-Passerini C; Scapozza L; Gueyrard D; Goekjian PG
Bioorg Med Chem; 2014 Feb; 22(4):1303-12. PubMed ID: 24468632
[TBL] [Abstract][Full Text] [Related]
2. Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.
Matsumaru T; Inai M; Ishigami K; Iwamatsu T; Maita H; Otsuguro S; Nomura T; Matsuda A; Ichikawa S; Sakaitani M; Shuto S; Maenaka K; Kan T
Bioorg Med Chem Lett; 2017 May; 27(10):2144-2147. PubMed ID: 28385506
[TBL] [Abstract][Full Text] [Related]
3. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
4. Palladium catalyzed one-pot sequential Suzuki cross-coupling-direct C-H functionalization of imidazo[1,2-a]pyrazines.
Gembus V; Bonfanti JF; Querolle O; Jubault P; Levacher V; Hoarau C
Org Lett; 2012 Dec; 14(23):6012-5. PubMed ID: 23151283
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
[TBL] [Abstract][Full Text] [Related]
6. Palladium-catalyzed direct heck arylation of dual pi-deficient/pi-excessive heteroaromatics. Synthesis of C-5 arylated imidazo[1,5-a]pyrazines.
Wang JX; McCubbin JA; Jin M; Laufer RS; Mao Y; Crew AP; Mulvihill MJ; Snieckus V
Org Lett; 2008 Jul; 10(14):2923-6. PubMed ID: 18576663
[TBL] [Abstract][Full Text] [Related]
7. Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities.
Yun JI; Yang EH; Latif M; Lee HJ; Lee K; Yun CS; Park CH; Lee CO; Chae CH; Cho SY; Jung HJ; Kim P; Choi SU; Kim HR
Arch Pharm Res; 2014 Jul; 37(7):873-81. PubMed ID: 24129617
[TBL] [Abstract][Full Text] [Related]
8. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
9. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
12. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: wild type and mutant (L1196M) active compounds with unique binding mode.
Gummadi VR; Rajagopalan S; Looi CY; Paydar M; Renukappa GA; Ainan BR; Krishnamurthy NR; Panigrahi SK; Mahasweta K; Raghuramachandran S; Rajappa M; Ramanathan A; Lakshminarasimhan A; Ramachandra M; Wong PF; Mustafa MR; Nanduri S; Hosahalli S
Bioorg Med Chem Lett; 2013 Sep; 23(17):4911-8. PubMed ID: 23880539
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
16. Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.
Schlütke L; Immer M; Preu L; Totzke F; Schächtele C; Kubbutat MHG; Kunick C
Eur J Pharm Biopharm; 2018 May; 126():89-94. PubMed ID: 28315448
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
18. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
19. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.
Geng K; Xia Z; Ji Y; Zhang RR; Sun D; Ai J; Song Z; Geng M; Zhang A
Eur J Med Chem; 2018 Jan; 144():386-397. PubMed ID: 29288940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
